ARHGAP35
ARHGAP35 (Rho GTPase-activating protein 35) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Bladder & urothelial cancer, Breast cancer and 5 more.
Overview
Rho GTPase-activating protein (GAP). Binds several acidic phospholipids which inhibits the Rho GAP activity to promote the Rac GAP activity. This binding is inhibited by phosphorylation by PRKCA.
CIViC holds 4 clinical evidence items and 0 assertions across 4 variants. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes literature 0.93, animal model 0.46, genetic association 0.00, somatic mutation 0.90). IntOGen calls it a driver in 15 cohorts (1 activating, 14 loss-of-function), covering Acute Myeloid Leukaemia, Basal Cell Carcinoma, Bladder Urothelial Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Lung Squamous Cell Carcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ARHGAP35 (Rho GTPase-activating protein 35) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Bladder & urothelial cancer, Breast cancer and 5 more.
- 1 · What it is
ARHGAP35 (Rho GTPase-activating protein 35) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Endometrial cancer, Bladder & urothelial cancer, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Rho GTPase-activating protein (GAP). Binds several acidic phospholipids which inhibits the Rho GAP activity to promote the Rac GAP activity.
- 3 · How drugs use it
No product in this corpus aims at ARHGAP35 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:4591 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NRY4 (protein name, function text, keywords and locations (REST API)); CIViC gene ARHGAP35 (4 evidence items, 0 assertions, 4 variants; diseases: (GraphQL API, CC0)); Open Targets ENSG00000160007 (association with cancer (MONDO_0004992) 0.75; per-cancer scores at or above 0.5: endometrial cancer 0.61, melanoma 0.56, skin cancer 0.56, breast cancer 0.57, lung cancer 0.51 (GraphQL API, CC0)); IntOGen ARHGAP35 (driver in 15 cohorts (Act 1, LoF 14); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Rho GTPase-activating protein (GAP). Binds several acidic phospholipids which inhibits the Rho GAP activity to promote the Rac GAP activity. This binding is inhibited by phosphorylation by PRKCA. Involved in cell differentiation as well as cell adhesion and migration, plays an important role in retinal tissue morphogenesis, neural tube fusion, midline fusion of the cerebral hemispheres and mammary gland branching morphogenesis. Transduces signals from p21-ras to the nucleus, acting via the ras GTPase-activating protein (GAP). Transduces SRC-dependent signals from cell-surface adhesion molecules, such as laminin, to promote neurite outgrowth. Location: Cytoplasm, cytoskeleton, cilium basal body; Cytoplasm; Nucleus; Cell membrane (UniProt). Locus 19q13.32 (HGNC).
- Endometrial cancer: Open Targets association 0.61 with endometrial cancer (MONDO_0011962); IntOGen driver in 4 cohorts (UCEC)
- Bladder & urothelial cancer: IntOGen driver in 3 cohorts (BLCA, UTUC)
- Breast cancer: Open Targets association 0.57 with breast cancer (MONDO_0007254); IntOGen driver in 2 cohorts (BRCA)
- Renal cell carcinoma: IntOGen driver in 1 cohort (CCRCC)
- Ovarian cancer: IntOGen driver in 1 cohort (OVT)
- Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 14 cohorts; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ARHGAP35" OR ABSTRACT:"ARHGAP35" OR TITLE:"Rho GTPase activating protein 35" OR ABSTRACT:"Rho GTPase activating protein 35" OR TITLE:"Rho GTPase-activating protein 35" OR ABSTRACT:"Rho GTPase-activating protein 35" OR TITLE:"GRF-1" OR ABSTRACT:"GRF-1" OR TITLE:"p190ARhoGAP" OR ABSTRACT:"p190ARhoGAP" OR TITLE:"P190A" OR ABSTRACT:"P190A") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARHGAP35, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetABL2
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetMECOM
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetPIK3CB
Shares Lung cancer (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetRAD51B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetBARD1
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetLZTR1
Shares Lung cancer (all types), Skin cancer (all types), Endometrial cancer, Breast cancer (all types).
- TargetKMT2C
Shares Lung cancer (all types), Renal cell carcinoma, Bladder & urothelial cancer, Breast cancer (all types).
- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.